Climb Bio (NASDAQ:CLYM) Earns Outperform Rating from Analysts at Leerink Partners

Analysts at Leerink Partners assumed coverage on shares of Climb Bio (NASDAQ:CLYM) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $10.00 price target on the stock. Leerink Partners’ price objective would suggest a potential upside of 205.81% from the company’s current price.

Climb Bio Stock Up 1.2 %

Shares of NASDAQ CLYM traded up $0.04 during midday trading on Monday, hitting $3.27. 896 shares of the stock traded hands, compared to its average volume of 455,574. Climb Bio has a one year low of $2.35 and a one year high of $11.55. The company has a market cap of $219.82 million, a price-to-earnings ratio of -1.54 and a beta of -0.34.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.